BACKGROUND Capecitabine is considered a first line agent in adjuvant therapy for breast and colorectal cancer. However,cases of severe diarrhea have been reported with increasing frequency in recent years. When diarrh...
Breast cancer (BC) is the most common malignancy in women and is second to lung cancer in terms of cancer mortality. Treatment of BC remains a challenge as current therapies are limited by toxicity and drug resistance...
Capecitabine (Xeloda) is an oral fluoropyrimidine which is produced as a pro-drug of fluorouracil, and shows improved tolerability and intratumor drug concentrations following its tumor-specif ic conversion to the a...